Fri Sep 20 12:16:12 UTC 2024: ## Evaxion Biotech A/S Receives “Buy” Rating from HC Wainwright, Target Price Set at $14.00

**New York, NY – September 20, 2024** – Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotech company focused on developing AI-powered immunotherapies, has received a reiterated “Buy” rating from equities researchers at HC Wainwright. The analysts have set a price target of $14.00 for the stock, representing a potential upside of 344.44% from its current price.

HC Wainwright’s positive outlook is based on Evaxion’s promising pipeline of cancer immunotherapies. The company is currently developing EVX-01 for metastatic melanoma (Phase IIb), EVX-02 for adjuvant melanoma (Phase 1/2a), and EVX-03 for various cancers (pre-clinical stage).

Evaxion recently reported its quarterly earnings on August 14th, missing analyst estimates with a loss of $0.12 per share and generating revenue of $0.15 million. Despite the miss, HC Wainwright remains confident in the company’s long-term potential, citing the potential of its innovative immunotherapies.

Evaxion’s stock opened at $3.15 on Friday, with a 52-week low of $2.26 and a 52-week high of $13.61. The company has a market capitalization of $17.04 million.

**Disclaimer:** This is a news article summarizing information from a research note. It does not constitute investment advice. Investors should conduct their own research before making any investment decisions.

Read More